Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi‐institutional study

Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron‐sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative st...

Full description

Saved in:
Bibliographic Details
Published inBJU international Vol. 109; no. 7; pp. 1013 - 1018
Main Authors Antonelli, Alessandro, Ficarra, Vincenzo, Bertini, Roberto, Carini, Marco, Carmignani, Giorgio, Corti, Serena, Longo, Nicola, Martorana, Giuseppe, Minervini, Andrea, Mirone, Vincenzo, Novara, Giacomo, Serni, Sergio, Simeone, Claudio, Simonato, Alchiede, Siracusano, Salvatore, Volpe, Alessandro, Zattoni, Filiberto, Cunico, Sergio Cosciani
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.04.2012
Wiley-Blackwell
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1464-4096
1464-410X
1464-410X
DOI10.1111/j.1464-410X.2011.10431.x

Cover

Loading…
Abstract Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron‐sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1). Patients with clinically organ‐confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer‐specific mortality both in cT1a and cT1b tumours OBJECTIVE •  To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ‐confined renal masses ≤7 cm in size (cT1). PATIENTS AND METHODS •  The records of 3480 patients with cT1N0M0 disease were extracted from a multi‐institutional database and analyzed retrospectively. RESULTS •  In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. •  With regard to the cT1a patients, the 5‐ and 10‐year cancer‐specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log‐rank test: P = 0.01). •  With regard to cT1b patients, the 5‐year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log‐rank test: P = 0.89). •  Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. •  Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log‐rank test: P = 0.91). CONCLUSIONS •  Elective PN is not associated with an increased risk of recurrence and cancer‐specific mortality in both cT1a and cT1b tumours. •  Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.
AbstractList To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1). The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively. In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91). Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.
Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron‐sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1). Patients with clinically organ‐confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer‐specific mortality both in cT1a and cT1b tumours OBJECTIVE •  To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ‐confined renal masses ≤7 cm in size (cT1). PATIENTS AND METHODS •  The records of 3480 patients with cT1N0M0 disease were extracted from a multi‐institutional database and analyzed retrospectively. RESULTS •  In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. •  With regard to the cT1a patients, the 5‐ and 10‐year cancer‐specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log‐rank test: P = 0.01). •  With regard to cT1b patients, the 5‐year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log‐rank test: P = 0.89). •  Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. •  Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log‐rank test: P = 0.91). CONCLUSIONS •  Elective PN is not associated with an increased risk of recurrence and cancer‐specific mortality in both cT1a and cT1b tumours. •  Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.
To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1).OBJECTIVETo compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1).The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively.PATIENTS AND METHODSThe records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively.In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91).RESULTSIn patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91).Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.CONCLUSIONSElective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.
Study Type - Therapy (cohort) Level of Evidence2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron-sparing surgery (NSS) in selected patients with 4.1cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1). Patients with clinically organ-confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer-specific mortality both in cT1a and cT1b tumours OBJECTIVE * To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7cm in size (cT1). PATIENTS AND METHODS * The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively. RESULTS * In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. * With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P=0.01). * With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P=0.89). * Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. * Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P=0.91). CONCLUSIONS * Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. * Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines. [PUBLICATION ABSTRACT]
Author Simonato, Alchiede
Cunico, Sergio Cosciani
Zattoni, Filiberto
Ficarra, Vincenzo
Corti, Serena
Novara, Giacomo
Minervini, Andrea
Martorana, Giuseppe
Carini, Marco
Bertini, Roberto
Siracusano, Salvatore
Mirone, Vincenzo
Simeone, Claudio
Carmignani, Giorgio
Antonelli, Alessandro
Longo, Nicola
Serni, Sergio
Volpe, Alessandro
Author_xml – sequence: 1
  givenname: Alessandro
  surname: Antonelli
  fullname: Antonelli, Alessandro
– sequence: 2
  givenname: Vincenzo
  surname: Ficarra
  fullname: Ficarra, Vincenzo
– sequence: 3
  givenname: Roberto
  surname: Bertini
  fullname: Bertini, Roberto
– sequence: 4
  givenname: Marco
  surname: Carini
  fullname: Carini, Marco
– sequence: 5
  givenname: Giorgio
  surname: Carmignani
  fullname: Carmignani, Giorgio
– sequence: 6
  givenname: Serena
  surname: Corti
  fullname: Corti, Serena
– sequence: 7
  givenname: Nicola
  surname: Longo
  fullname: Longo, Nicola
– sequence: 8
  givenname: Giuseppe
  surname: Martorana
  fullname: Martorana, Giuseppe
– sequence: 9
  givenname: Andrea
  surname: Minervini
  fullname: Minervini, Andrea
– sequence: 10
  givenname: Vincenzo
  surname: Mirone
  fullname: Mirone, Vincenzo
– sequence: 11
  givenname: Giacomo
  surname: Novara
  fullname: Novara, Giacomo
– sequence: 12
  givenname: Sergio
  surname: Serni
  fullname: Serni, Sergio
– sequence: 13
  givenname: Claudio
  surname: Simeone
  fullname: Simeone, Claudio
– sequence: 14
  givenname: Alchiede
  surname: Simonato
  fullname: Simonato, Alchiede
– sequence: 15
  givenname: Salvatore
  surname: Siracusano
  fullname: Siracusano, Salvatore
– sequence: 16
  givenname: Alessandro
  surname: Volpe
  fullname: Volpe, Alessandro
– sequence: 17
  givenname: Filiberto
  surname: Zattoni
  fullname: Zattoni, Filiberto
– sequence: 18
  givenname: Sergio Cosciani
  surname: Cunico
  fullname: Cunico, Sergio Cosciani
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25647087$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21883829$$D View this record in MEDLINE/PubMed
BookMark eNqVks1u1DAQxy1URD_gFZAlhLiwwY6dxOGABFX5UiUurcTNmvU6qleJvbWdtnvjEXgdXocnYbK7LdKewAd7PP7NeDz-H5MDH7wlhHJWcBxvlgWXtZxJzr4XJeO84EwKXtw9IkcPBwf3NmvrQ3Kc0pIxdNTVE3JYcqWEKtsj8uustya7G0tXELODnnq7uoroC8OaukTt9ehuoLc-0xxohIUz-5DH2OyQSPTW5Stqeuc31AWn0Xo0jO1xgmicDwO8RW8ae8RDRwE3OYa02pbxmpowYCmw3QyIud8_fjqfsstjdmFKl_K4WD8ljzvok322W0_I5cezi9PPs_Nvn76cvj-fGVk2fKZMVyomYdE1HVSCzaVqSwsWeMWFZKY2dcmaeS2EamXXAbCqxWPOreWVARAn5NU27yqG69GmrAeXpgeBt2FMui2VqFveSCRf7JHLMEYsOGkuKiEq2bIKqec7apwPdqFX0Q0Q1_r-TxB4uQMgYRe7CN649Jeratkw1SCntpzB9qVouweEMz3JRC_1pAA9qUFPMtEbmeg7DH23F2pchqm7OYLr_yPBrevt-p8v1h--Xm5M8Qfnudvw
CODEN BJINFO
CitedBy_id crossref_primary_10_1016_j_euo_2019_02_006
crossref_primary_10_1186_s40001_014_0058_4
crossref_primary_10_1016_j_urology_2018_12_020
crossref_primary_10_1097_MOU_0b013e3283551f84
crossref_primary_10_1186_s12894_022_01088_3
crossref_primary_10_1016_j_euf_2015_04_001
crossref_primary_10_1007_s11255_017_1525_y
crossref_primary_10_1097_MOU_0b013e328363a5c0
crossref_primary_10_1007_s40477_019_00413_1
crossref_primary_10_1634_theoncologist_2016_0435
crossref_primary_10_1111_bju_13353
crossref_primary_10_1177_0300891619853392
crossref_primary_10_1016_j_juro_2014_07_112
crossref_primary_10_1016_j_juro_2017_03_145
crossref_primary_10_1007_s00261_023_04146_y
crossref_primary_10_1016_j_eururo_2012_02_039
crossref_primary_10_1016_j_juro_2016_01_099
crossref_primary_10_1007_s00345_012_0943_9
crossref_primary_10_1177_03915603221140964
crossref_primary_10_3390_cancers15030909
crossref_primary_10_1111_iju_12204
crossref_primary_10_1148_radiol_13130221
crossref_primary_10_17650_2070_9781_2023_24_3_66_74
crossref_primary_10_1007_s00345_013_1136_x
crossref_primary_10_1016_j_eururo_2014_09_027
crossref_primary_10_1111_iju_12603
crossref_primary_10_1016_j_ajur_2019_11_004
crossref_primary_10_1111_bju_13888
crossref_primary_10_1590_s1677_5538_ibju_2020_0930
crossref_primary_10_1016_j_ijsu_2016_05_031
crossref_primary_10_1002_cam4_2993
crossref_primary_10_1016_j_clgc_2020_06_007
crossref_primary_10_1007_s00464_015_4382_8
crossref_primary_10_1007_s00270_012_0470_5
crossref_primary_10_3233_KCA_230001
crossref_primary_10_1089_end_2014_0517
crossref_primary_10_1097_MD_0000000000040721
crossref_primary_10_1148_radiol_2020200149
crossref_primary_10_1016_j_acra_2024_08_007
crossref_primary_10_1016_j_suronc_2016_09_001
crossref_primary_10_1177_107327481302000310
crossref_primary_10_1111_iju_13009
crossref_primary_10_1002_14651858_CD012045_pub2
crossref_primary_10_1016_j_ijsu_2016_03_038
crossref_primary_10_1016_j_juro_2016_04_081
crossref_primary_10_1097_MOU_0b013e32835ddab6
crossref_primary_10_1186_s12894_019_0480_6
crossref_primary_10_1111_bju_12204
crossref_primary_10_24060_2076_3093_2024_14_1_13_19
crossref_primary_10_1159_000443672
crossref_primary_10_1002_jbm_b_34637
crossref_primary_10_1089_end_2013_0197
crossref_primary_10_1016_j_ejso_2014_12_001
crossref_primary_10_1186_s12957_024_03302_y
crossref_primary_10_1089_end_2015_0411
crossref_primary_10_1089_end_2020_0314
crossref_primary_10_1586_erd_12_94
crossref_primary_10_1016_j_urolonc_2016_12_011
crossref_primary_10_1111_bju_13627
crossref_primary_10_1186_1471_2407_14_372
crossref_primary_10_1016_j_eururo_2016_08_060
crossref_primary_10_1200_JCO_2016_69_9645
crossref_primary_10_1016_j_urology_2015_05_013
crossref_primary_10_1111_bju_12570
crossref_primary_10_1245_s10434_017_5831_5
crossref_primary_10_1007_s00345_016_1923_2
crossref_primary_10_1002_jso_24695
crossref_primary_10_1007_s12325_013_0061_0
crossref_primary_10_1111_iju_13544
crossref_primary_10_1016_j_urology_2015_08_049
Cites_doi 10.1097/01.ju.0000124846.37299.5e
10.1016/j.eururo.2010.08.001
10.1016/j.eururo.2007.11.007
10.1016/j.eururo.2006.11.013
10.1097/01.ju.0000135837.64840.55
10.1007/978-1-4757-3656-4
10.1016/j.urology.2008.08.492
10.1016/j.eururo.2009.07.040
10.1097/00000478-198210000-00007
10.1016/j.eururo.2010.04.033
10.1016/j.eururo.2010.06.032
10.1111/j.1464-410X.2006.06060.x
10.1016/j.eururo.2009.10.019
10.1097/01.ju.0000113274.40885.db
10.1016/j.ejso.2008.07.008
10.1016/S1470-2045(06)70803-8
10.1016/S0022-5347(17)68620-8
10.1016/j.eururo.2009.10.023
10.1016/j.juro.2009.05.035
10.1200/JCO.1999.17.9.2868
10.1016/S0022-5347(17)62331-0
10.1016/S0022-5347(05)67793-2
ContentType Journal Article
Copyright 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL
2015 INIST-CNRS
2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
Copyright_xml – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL
– notice: 2015 INIST-CNRS
– notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
CorporateAuthor members of the SATURN Project – LUNA Foundation
members of the SATURN Project - LUNA Foundation
CorporateAuthor_xml – name: members of the SATURN Project – LUNA Foundation
– name: members of the SATURN Project - LUNA Foundation
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7X8
DOI 10.1111/j.1464-410X.2011.10431.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1464-410X
EndPage 1018
ExternalDocumentID 2975476721
21883829
25647087
10_1111_j_1464_410X_2011_10431_x
BJU10431
Genre article
Multicenter Study
Journal Article
Comparative Study
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QP
1OB
7X8
ID FETCH-LOGICAL-c4271-8cf2804adf7fa530b4892eaea151340c6c6207b633894ffaa059eae11ee15caa3
IEDL.DBID DR2
ISSN 1464-4096
1464-410X
IngestDate Tue Aug 05 10:32:57 EDT 2025
Fri Jul 25 06:36:47 EDT 2025
Thu Apr 03 07:07:35 EDT 2025
Mon Jul 21 09:14:16 EDT 2025
Tue Jul 01 03:49:52 EDT 2025
Thu Apr 24 23:44:10 EDT 2025
Wed Jan 22 16:20:39 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Kidney disease
Human
Nephrology
Urinary system disease
Carcinoma
clinical staging
radical nephrectomy
Staging
Stage classification
renal cancer
Malignant tumor
partial nephrectomy
Retrospective
Urology
Conservative surgery
Treatment
nephron-sparing surgery
Nephrectomy
Partial
Kidney cancer
Nephron
Grawitz tumor
Comparative study
Cancer
Language English
License CC BY 4.0
2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4271-8cf2804adf7fa530b4892eaea151340c6c6207b633894ffaa059eae11ee15caa3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
PMID 21883829
PQID 1353354905
PQPubID 1026371
PageCount 6
ParticipantIDs proquest_miscellaneous_928369174
proquest_journals_1353354905
pubmed_primary_21883829
pascalfrancis_primary_25647087
crossref_primary_10_1111_j_1464_410X_2011_10431_x
crossref_citationtrail_10_1111_j_1464_410X_2011_10431_x
wiley_primary_10_1111_j_1464_410X_2011_10431_x_BJU10431
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2012
PublicationDateYYYYMMDD 2012-04-01
PublicationDate_xml – month: 04
  year: 2012
  text: April 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
– name: Edgecliff
PublicationTitle BJU international
PublicationTitleAlternate BJU Int
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Wiley-Blackwell
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley-Blackwell
– name: Wiley Subscription Services, Inc
References 2009; 56
2009; 35
2006; 97
2009; 73
2010; 58
2010; 57
1950; 64
2009; 182
1999; 17
1982; 6
2004; 172
2004; 171
2006; 7
2009
2000; 163
2004
2007; 51
2008; 53
2002
1969; 101
e_1_2_7_5_2
e_1_2_7_4_2
e_1_2_7_3_2
e_1_2_7_2_2
e_1_2_7_9_2
Greene FL (e_1_2_7_16_2) 2002
e_1_2_7_8_2
e_1_2_7_7_2
e_1_2_7_6_2
e_1_2_7_19_2
e_1_2_7_18_2
e_1_2_7_15_2
e_1_2_7_14_2
e_1_2_7_25_2
e_1_2_7_13_2
e_1_2_7_24_2
e_1_2_7_12_2
e_1_2_7_23_2
e_1_2_7_11_2
e_1_2_7_22_2
e_1_2_7_10_2
e_1_2_7_21_2
e_1_2_7_20_2
Eble JN (e_1_2_7_17_2) 2004
References_xml – volume: 56
  start-page: 786
  year: 2009
  end-page: 93
  article-title: Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron‐sparing surgery
  publication-title: Eur Urol
– year: 2009
– volume: 97
  start-page: 939
  year: 2006
  end-page: 45
  article-title: Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm
  publication-title: BJU Int
– volume: 57
  start-page: 223
  year: 2010
  end-page: 32
  article-title: A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer
  publication-title: Eur Urol
– volume: 171
  start-page: 2181
  year: 2004
  end-page: 5
  article-title: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience
  publication-title: J Urol
– volume: 17
  start-page: 2868
  year: 1999
  end-page: 75
  article-title: Efficacy of nephron‐sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor‐node‐metastasis staging system
  publication-title: J Clin Oncol
– volume: 58
  start-page: 398
  year: 2010
  end-page: 406
  article-title: EAU guidelines on renal cell carcinoma: the 2010 update
  publication-title: Eur Urol
– volume: 58
  start-page: 655
  year: 2010
  end-page: 68
  article-title: Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors
  publication-title: Eur Urol
– year: 2002
– volume: 35
  start-page: 636
  year: 2009
  end-page: 42
  article-title: The use of partial nephrectomy in european tertiary care centers
  publication-title: Eur J Surg Oncol
– volume: 182
  start-page: 844
  year: 2009
  end-page: 53
  article-title: The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth
  publication-title: J Urol
– year: 2004
– volume: 64
  start-page: 200
  year: 1950
  end-page: 8
  article-title: Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma
  publication-title: J Urol
– volume: 172
  start-page: 858
  year: 2004
  end-page: 62
  article-title: Multi‐institutional validation of a symptom based classification for renal cell carcinoma
  publication-title: J Urol
– volume: 51
  start-page: 1606
  year: 2007
  end-page: 15
  article-title: A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron‐sparing surgery and radical nephrectomy for low‐stage renal cell carcinoma
  publication-title: Eur Urol
– volume: 53
  start-page: 803
  year: 2008
  end-page: 9
  article-title: Nephron‐sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm
  publication-title: Eur Urol
– volume: 73
  start-page: 1300
  year: 2009
  end-page: 5
  article-title: Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics
  publication-title: Urology
– volume: 171
  start-page: 1066
  year: 2004
  end-page: 70
  article-title: Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy
  publication-title: J Urol
– volume: 6
  start-page: 655
  year: 1982
  end-page: 63
  article-title: Prognostic significance of morphologic parameters in renal cell carcinoma
  publication-title: Am J Surg Pathol
– volume: 163
  start-page: 730
  year: 2000
  end-page: 6
  article-title: Surgical management of renal tumors 4 cm. or less in a contemporary cohort
  publication-title: J Urol
– volume: 7
  start-page: 735
  year: 2006
  end-page: 40
  article-title: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study
  publication-title: Lancet Oncol
– volume: 58
  start-page: 293
  year: 2010
  end-page: 8
  article-title: Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticiapted benign renal tumours
  publication-title: Eur Urol
– volume: 101
  start-page: 297
  year: 1969
  end-page: 301
  article-title: The results of radical nephrectomy for renal cell carcinoma
  publication-title: J Urol
– volume: 57
  start-page: 214
  year: 2010
  end-page: 22
  article-title: The expanding role of partial nephrectomy: a critical analysis of indications, results and complications
  publication-title: Eur Urol
– ident: e_1_2_7_11_2
  doi: 10.1097/01.ju.0000124846.37299.5e
– ident: e_1_2_7_23_2
  doi: 10.1016/j.eururo.2010.08.001
– ident: e_1_2_7_14_2
  doi: 10.1016/j.eururo.2007.11.007
– ident: e_1_2_7_7_2
  doi: 10.1016/j.eururo.2006.11.013
– ident: e_1_2_7_15_2
  doi: 10.1097/01.ju.0000135837.64840.55
– volume-title: American Joint Committee on Cancer (AJCC) Staging Manual
  year: 2002
  ident: e_1_2_7_16_2
  doi: 10.1007/978-1-4757-3656-4
– ident: e_1_2_7_22_2
  doi: 10.1016/j.urology.2008.08.492
– ident: e_1_2_7_25_2
  doi: 10.1016/j.eururo.2009.07.040
– ident: e_1_2_7_18_2
  doi: 10.1097/00000478-198210000-00007
– ident: e_1_2_7_5_2
  doi: 10.1016/j.eururo.2010.04.033
– volume-title: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs
  year: 2004
  ident: e_1_2_7_17_2
– ident: e_1_2_7_8_2
  doi: 10.1016/j.eururo.2010.06.032
– ident: e_1_2_7_13_2
  doi: 10.1111/j.1464-410X.2006.06060.x
– ident: e_1_2_7_6_2
  doi: 10.1016/j.eururo.2009.10.019
– ident: e_1_2_7_12_2
  doi: 10.1097/01.ju.0000113274.40885.db
– ident: e_1_2_7_21_2
  doi: 10.1016/j.ejso.2008.07.008
– ident: e_1_2_7_4_2
  doi: 10.1016/S1470-2045(06)70803-8
– ident: e_1_2_7_3_2
  doi: 10.1016/S0022-5347(17)68620-8
– ident: e_1_2_7_10_2
  doi: 10.1016/j.eururo.2009.10.023
– ident: e_1_2_7_9_2
– ident: e_1_2_7_24_2
  doi: 10.1016/j.juro.2009.05.035
– ident: e_1_2_7_20_2
  doi: 10.1200/JCO.1999.17.9.2868
– ident: e_1_2_7_2_2
  doi: 10.1016/S0022-5347(17)62331-0
– ident: e_1_2_7_19_2
  doi: 10.1016/S0022-5347(05)67793-2
SSID ssj0014665
Score 2.3312435
SecondaryResourceType review_article
Snippet Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for...
To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal...
Study Type - Therapy (cohort) Level of Evidence2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1013
SubjectTerms Biological and medical sciences
Cancer
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - surgery
clinical staging
Elective Surgical Procedures
Female
Humans
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Kidney Neoplasms - surgery
Kidneys
Male
Medical research
Medical sciences
Middle Aged
Mortality
Nephrectomy - methods
Nephrology. Urinary tract diseases
nephron‐sparing surgery
partial nephrectomy
radical nephrectomy
renal cancer
Survival Rate
Tumors of the urinary system
Title Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi‐institutional study
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10431.x
https://www.ncbi.nlm.nih.gov/pubmed/21883829
https://www.proquest.com/docview/1353354905
https://www.proquest.com/docview/928369174
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LatwwFBUli1IofT_cpkGLLuNBsmVZ011bEkIgXZQMzE7IGhmGTOzJ2Ia2q35Cf6e_0y_pvZLt4JBFKN35oSuPRkfSkXR1LiHvZWGZSe0qTq0VMTBiFRtmLTQ8zlcWYF0UuN5x9kWeLMTpMlv2_k94FiboQ4wLbtgyfH-NDdwUzc1GDtlztgxKnBx1YmbIJ9F1C_nR11FJCpL6qJLBBGj71Knn1owmI9XDrWngTytDtIvb6OiU3frh6fgxuRgKFrxSLmZdW8zsjxuaj_-n5E_Io57F0o8Bdk_JPVc9I_fP-n365-T30SZ0pHSL0ISklUPU2La-_E7XDXVX3RowDiMebWu6M363aJqoor3ma0NxsZgOZzjpOac7h5_HTQdqMRhSVV-aD_C06TaQvC6pgZt2Vw_nSA-pvVY5P6Tei_LPz1_r3lPCL4dSr7T7giyOj84_n8R9kIjYiiTnsbJlopgwqzIvTZayQqh54owzQGVSway0MmF5IWEqPhdlaQzwSXjNuXM8s8akL8leVVfuNaFSMelWiXLIylQmVcFSscqzMnHMSZdEJB8AoW2voI6BPDZ6MpMSGmtGY81oXzP6W0T4aLkNKiJ3sDmYYG40BJIqcqbyiOwPINR9x9NoDGOSwpyfZRGh42voMrBKTOXqrtFzoJQSpukiIq8Cdq_z5kqlKplDUT0C7_xr9afThb9888-Wb8kDeJ4Et6h9stfuOvcOGF9bHPi2_BcPW0s-
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLbQkAAJ8Q8LjOELLpfKThzH5Y6fTWWsu0Ct1DvLcR2pWpeUJpEGVzwCr8Pr8CQc20mmTLuYEHdtc45b19-xPx8fn4PQW55pomK9DGOtWQiMWISKaA2GR-lSA6yzzPo7pqd8MmfHi2TRlgOyd2F8foje4WYtw83X1sCtQ_qqlUP7lCx8Kk5qE8WMgFDetgW-bTmDT1_7XFIg6-pKeh0g7sOwnmtbGqxV9zeqgr8t9_UuriOkQ37rFqijh2jddc3HpZyNmjob6R9Xsj7-p74_Qg9aIovfe-Q9RrdM8QTdmbZH9U_R78O1n0vxxqITRAtjgaPr8vw7XlXYfGtWAHNY9HBd4q1yB0ZDoQK3aV8rbP3FuLvGiWcUb439envugLWth1SU5-odfFo1axAvc6zgTb0tu6ukB1hfJjo_wC6Q8s_PX6s2WMJ5RLFLtvsMzY8OZx8nYVsnItQsSmkodB4JwtQyT3OVxCRjYhwZZRSwmZgRzTWPSJpx2I2PWZ4rBZQSHlNqDE20UvFztFOUhdlFmAvCzTISxhIzkXCRkZgt0ySPDDHcRAFKO0RI3SZRt7U81nKwmWLSjoy0IyPdyMiLANFec-MTidxAZ38Aul4ReCpLiUgDtNehULZzTyVtJZMYtv0kCRDuH8OsYYdEFaZsKjkGVslhp84C9MKD97JtKkQsojF01UHwxr9Wfjieu5cv_1nzDbo7mU1P5Mnn0y-v0D2QiXyU1B7aqbeNeQ0EsM72nWH_BaBET1g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQkSokxP9PoBQfODYrO3EcLzd-uiqFVgh1pb1ZjuNIq26TZZNILScegdfhdXgSxnaSKlUPFeK22cw4cfyN_dkezyD0hmeaqFjnYaw1C4ERi1ARrcHwKM01wDrL7HrH0TE_mLPDRbLo_J_sWRgfH2JYcLOW4fpra-DrvLhq5FA8JQsfiZPaODET4JO3GYeHWIL0bQglBbIuraTXAd4-9uq5tqTRUHV3rWr4aoVPd3EdHx3TWzc-ze6j075m3i3ldNI22UT_uBL08f9U_QG619FY_M7j7iG6ZcpHaPuo26h_jH7vr3xPitcWmyBaGgsb3VRnF3hZY_O9XQLIYcjDTYU3ym0XjYVK3AV9rbFdLcb9IU58QvHG2MfbXQesbTaksjpTb-Hful2BeFVgBRfNpuoPku5hfRnmfA87N8o_P38tO1cJtx6KXajdJ2g-2z_5cBB2WSJCzaKUhkIXkSBM5UVaqCQmGRPTyCijgMvEjGiueUTSjMNcfMqKQikglHCbUmNoopWKn6KtsirNc4S5INzkkTCWlomEi4zELE-TIjLEcBMFKO0BIXUXQt1m8ljJ0VSKSdsy0raMdC0jzwNEB821DyNyA53dEeYGRWCpLCUiDdBOD0LZ9Ty1tHlMYpj0kyRAeLgNfYZtElWaqq3lFDglh3k6C9Azj93LsqkQsYimUFWHwBu_rXx_OHc_X_yz5mu0_fXjTH75dPz5JboDIpF3kdpBW82mNa-A_TXZrjPrv42pThA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elective+partial+nephrectomy+is+equivalent+to+radical+nephrectomy+in+patients+with+clinical+T1+renal+cell+carcinoma%3A+results+of+a+retrospective%2C+comparative%2C+multi-institutional+study&rft.jtitle=BJU+international&rft.au=Antonelli%2C+Alessandro&rft.au=Ficarra%2C+Vincenzo&rft.au=Bertini%2C+Roberto&rft.au=Carini%2C+Marco&rft.date=2012-04-01&rft.issn=1464-410X&rft.eissn=1464-410X&rft.volume=109&rft.issue=7&rft.spage=1013&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10431.x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon